Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
H Zahir, J Greenberg, C Hsu… - Clinical …, 2023 - Wiley Online Library
Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
Effect of mild and moderate hepatic impairment (defined by Child–Pugh classification and National Cancer Institute Organ Dysfunction Working Group criteria) on …
H Zahir, J Greenberg, C Hsu… - The Journal of …, 2022 - Wiley Online Library
Pexidartinib is a novel oral small‐molecule tyrosine kinase inhibitor targeting the colony‐
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
[HTML][HTML] Evaluation of absorption and metabolism-based DDI potential of pexidartinib in healthy subjects
H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - Springer
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
Evaluation of potential drug‐drug interaction risk of pexidartinib with substrates of cytochrome P450 and P‐glycoprotein
H Zahir, F Kobayashi, C Zamora… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
[HTML][HTML] A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, TWW Chen, CH Hsu, YH Yen… - Investigational New …, 2020 - Springer
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor or other solid tumors
O Yin, AJ Wagner, J Kang, W Knebel… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is a kinase inhibitor that induces tumor response and improvements in
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug …
H Zahir, O Yin, C Hsu, AJ Wagner… - Clinical …, 2023 - Wiley Online Library
Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure
S Nakayama, V Lukacova, S Tanabe… - Clinical …, 2024 - Wiley Online Library
Pexidartinib is a systemic treatment for patients with tenosynovial giant cell tumor not
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …
amenable to surgery. Oral absorption of pexidartinib is affected by food; administration with …
Correction to: pexidartinib: first approval
YN Lamb - Drugs, 2020 - Springer
Correction to: Pexidartinib: First Approval | Drugs Skip to main content SpringerLink Account
Menu Find a journal Publish with us Search Cart 1.Home 2.Drugs 3.Article Correction to …
Menu Find a journal Publish with us Search Cart 1.Home 2.Drugs 3.Article Correction to …
[HTML][HTML] Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional …
C McCabe, H Wright, K Polson, AJ Wagner - Orphanet Journal of Rare …, 2023 - Springer
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …